This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Michiel van der Heijden group


Michiel van der Heijden

Group leader

Personal details


Michiel van der Heijden graduated from medical school at the Erasmus University in Rotterdam, The Netherlands in 2002. His research experience has been focused on molecular biology and included an internship of one year (1999) at the department of Neurosurgery, University of Maryland(Baltimore, USA) and a 2-year (2002-2004) fellowship in the lab of Scott Kern, Sydney Kimmel Cancer Center Johns Hopkins University (Baltimore-USA).

He successfully defended his thesis "The Fanconi anemia/BRCA2 pathway in pancreatic cancer" on September 15, 2005. He then started his residency in internal medicine/medical oncology. This residency was interrupted from 2009-2011 when he joined the lab of Rene Bernards as a postdoc, working on molecular resistance to targeted therapy in breast and colon cancer. He was one of the applicants on a 4-year project grant from the Dutch cancer foundation (KWF): "Identification of genetic modifiers of sensitivity to mTOR pathway inhibition in breast cancer".

April 1, 2013, he graduated as a medical oncologist and started a combined clinical/research position at the Netherlands Cancer Institute / Antoni van Leeuwenhoek hospital, specializing in urological cancers with a main focus on bladder cancer.

Share this page